Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

Cronos Group Inc.

Rank #439HypergrowthWatchlistCompare with other stocks

CRON · Nasdaq · Healthcare

Cronos Group Inc. (CRON) — Rank #439 by gross profitability (GP/assets 0.05) · ROE -0.9% · Piotroski F-Score 6 / 9.

As-of 2026-10-30 · CIK 0001656472 · all metrics point-in-time as of the filing date.

About

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally.

Show more

It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.

The company is headquartered in Stayner, Canada.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
State
A1
Filer Category
Accelerated filer
Fiscal Year End
December 31

Company Snapshot

P/S is the primary valuation lens — earnings are reinvested, not available for P/E.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

610

Industry

Drug Manufacturers - Specialty & Generic

Exchange

Nasdaq

12/12

Flags passed

CRON passes 12/12 quality flags

  • PASS
    Gross margin holding
  • PASS
    Dilution within 2%
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Revenue not declining
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    Balance sheet stable
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Sequential beat (rev + EPS)

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.05
Return on equity
-0.9%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.06
Current ratio
16.18×
Net cash
$801.55M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
4.8%

Growth

2/2 pass
Revenue growth
24.6%
Piotroski F-Score
6 / 9
Share dilution
-0.5%

Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.

Profitability

Does it make money well?

No warning flags · GP/assets 5th percentile of 39 SIC 28 peers

Gross profitability (GP / assets)

0.05

Primary signal (Novy-Marx).

5th pctl of 39 SIC 28 peers

Return on equity

-0.9%

Gross margin

42.8%

47th pctl of 39 SIC 28 peers

Revenue growth (YoY)

24.6%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

19.1%

Revenue CAGR (5Y)

25.7%

Earnings CAGR (3Y)

—

FCF CAGR (3Y)

—

Cash Flow Health

Is the cash real?

No warning flags · FCF 102% above net income

Free cash flow

$149.00K

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

101.6%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

4.8%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

No warning flags · net cash $801.55M, F-Score 6/9

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.06

100th pctl of 35 SIC 28 peers (best = lowest)

Current ratio

16.18×

100th pctl of 39 SIC 28 peers

Quick ratio

14.79×

Net cash

$801.55M

Cash & equivalents minus total debt.

Piotroski F-Score

6 / 9

Fundamental-strength score (0-9).

Valuation

Is the price reasonable?

No warning flags

Capital allocation quality

Composite score

3.0 / 5

Good
Share count trend(net buybacks)
-0.5%3/5 Good
Buyback timing
N/AN/A
Dividend growth consistency(non-payer or broken streak)
0 yr3/5 Good
Net debt trajectory
-1.9%3/5 Good

Lifecycle Phase History

20202025
Hypergrowth
Startup

Price History

CRON-44.6% · -11.1% CAGRSPY+82.9% · +12.8% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports